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Abstract: Novel DNA sequencing techniques, referred to as “next-generation” sequencing 
(NGS),  provide  high  speed  and  throughput  that  can  produce  an  enormous  volume  of 
sequences  with  many  possible  applications  in  research  and  diagnostic  settings.  In  this 
article, we provide an overview of the many applications of NGS in diagnostic virology. 
NGS techniques have been used for high-throughput whole viral genome sequencing, such 
as  sequencing  of  new  influenza  viruses,  for  detection  of  viral  genome  variability  and 
evolution within the host, such as investigation of human immunodeficiency virus  and 
human  hepatitis  C  virus  quasispecies,  and  monitoring  of  low-abundance  antiviral  
drug-resistance  mutations.  NGS  techniques  have  been  applied  to  metagenomics-based 
strategies for the detection of unexpected disease-associated viruses and for the discovery of 
novel  human  viruses,  including  cancer-related  viruses.  Finally,  the  human  virome  in 
healthy and disease conditions has been described by NGS-based metagenomics.  
Keywords: next generation sequencing; deep sequencing; virus discovery; metagenomics; 
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resistance; minority variants 
 




Novel DNA sequencing techniques, referred to as “next-generation” sequencing (NGS), provide 
high speed and throughput that can produce an enormous volume of sequences. The most important 
advantage provided by these platforms is the determination of the sequence data from single DNA 
fragments of a library that are segregated in chips, avoiding the need for cloning in vectors prior to 
sequence acquisition.  
The  first  next-generation  high-throughput  sequencing  technology,  the  454  FLX  pyrosequencing 
platform  (http://www.454.com/),  which  was  developed  by  454  Life  Sciences  and  later  bought  
by  Roche,  became  available  in  2005.  In  early  2007,  Illumina  released  the  Genome  Analyzer 
(http://www.illumina.com),  developed  by  Solexa  GA,  and  more  recently,  SOLiD  was  released  by 
Applied Biosystems (http://www.appliedbiosystems.com). This field is in rapid expansion and novel 
and improved platforms are continuously being developed and released, like Heliscope by Helicos 
(http://www.helicosbio.com/),  Ion Torrent PGM by  Life Technologies (http://www.iontorrent.com/) 
and a real-time sequencing platform by Pacific Biosciences (http://www.pacificbiosciences.com/). 
While the platform developed by Pacific Biosciences, as well as other novel sequencing platforms, 
are referred as “third-generation” because they sequence processively single large DNA molecules 
without the need to halt between read steps, 454 pyrosequencing, Illumina GA and SOLiD methods 
represent the “second generation” systems, able to sequence populations of amplified template-DNA 
molecules with a typical “wash-and-scan” technique [1]. Given these criteria, Ion Torrent PGM and 
Heliscope sit between “second-” and “third-generation” technologies, since they do not completely 
fulfill the features assigned to each category.  
These NGS methods have different underlying biochemistries and differ in sequencing protocol 
(sequencing by synthesis for 454 pyrosequencing,  Illumina GA,  Ion  Torrent PGM  and  Heliscope, 
sequencing by ligation for SOLiD), throughput, and for sequence length (Table 1). Thus, the SOLiD 
system may be more suitable for applications that require a very high throughput of sequences, but not 
long reads, such as whole genome re-sequencing or RNA-sequencing projects, while both 454 and 
Illumina provide data suitable for de novo assembly and the relative long length of 454 FLX (and its 
smaller version GS Junior) reads allows deep sequencing of amplicons, with applications in microbial 
and viral metagenomics and analysis of viral quasispecies, as described in this review. The technical 
features  of  NGS  methods  (reviewed  in  refs.  [2,3])  will  not  be  described  in  this  review,  which  is 
focused on the diagnostic applications of NGS in clinical virology. 
Table 1. Features of “next-generation” sequencing (NGS) platforms. 
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Table 1. Cont. 







Applications  Main source of errors 
Illumina  6,000  ~100  10
−2–10









amplification, low coverage 
of AT rich regions 
SOLiD  20,000  ~50  10
−2–10




Signal interference among 
neighbours, phasing, 
nucleotide labeling, signal 
degradation, mixed beads, 





−2  Non amplifiable 








1,000  ~200  3 × 10










GS Junior  ~35  ~400  10
−3–10
−4  Target resequencing 
(amplicons), genotyping 
Intensity cutoff, 
homopolymers, signal  
cross-talk interference among 
neighbors, amplification, 
mixed beads 
* Error rate considering only substitutions and not insertions/deletions. 
2. Applications of NGS Technologies to Diagnostic Virology 
NGS  technologies  are  currently  used  for  whole  genome  sequencing,  investigation  of  genome 
diversity, metagenomics, epigenetics, discovery of non-coding RNAs and protein-binding sites, and 
gene-expression profiling by RNA sequencing (reviewed in refs. [2–6]). Typical applications of NGS 
methods  in  microbiology  and  virology,  besides  high-throughput  whole  genome  sequencing,  are 
discovery  of  new  microorganisms  and  viruses  by  using  metagenomic  approaches,  investigation  of 
microbial communities in the environment and in human body niches in healthy and disease conditions, 
analysis  of  viral  genome  variability  within  the  host  (i.e.,  quasispecies),  detection  of  
low-abundance antiviral drug-resistance mutations in patients with human immunodeficiency  virus 
(HIV) infection or viral hepatitis, as outlined in this review article.  Int. J. Mol. Sci. 2011, 12  7864 
 
 
2.1. Detection of Unknown Viral Pathogens and Discovery of Novel Viruses 
The human population is exposed to an increasing burden of infectious diseases caused by the 
emergence of new previously unrecognized viruses. Climate changes, globalization, settlements near 
animal and livestock habitats, and the increased number of immunocompromised people probably 
contribute to the emergence and spread of new infections [7]. In addition, several clinical syndromes 
are suspected to be of  viral etiology, but the causing  agent cannot be  isolated and recognized by 
traditional  culture  and  molecular  methods.  Thus,  there  is  the  need  to  improve  methods  for  the 
identification  of  unsuspected  viral  pathogens  or  new  viruses.  Subtractive  techniques,  such  as 
representational difference analysis or random sequencing of plasmid libraries of nuclease resistant 
fragments of viral genomes, have led in the past to the discovery of several viruses, including human 
herpesvirus  type  8  [8],  human  GB  virus  [9],  Torque  Teno  Virus  [10],  bocavirus  [11],  human 
parvovirus 4 [12], WU polyomavirus [13] and KI polyomavirus [14]. These techniques are poorly 
sensitive and time-consuming, and thus are unsuitable for large scale analysis. For these purposes, 
NGS-based methods have been developed. However, traditional cloning and sequencing methods can 
be relatively simple and sensitive for the discovery of new viruses when used for the analysis of 
otherwise sterile samples, and may represent an alternative to NGS. One of these methods is termed 
VIDISCA (Virus Discovery cDNA Amplified Fragment Length Polymorphism Analysis) and may be 
applied to sterile specimens, such as cell culture supernatants [15]. In this method, samples are ultra-
centrifuged for viral particle enrichment and treated by DNase and RNase to digest away cellular 
nucleic  acids.  Capsid-protected  viral  nucleic  acids  are  then  purified,  converted  to  double  stranded 
DNA, digested with restriction enzymes and ligated to oligonucleotide adaptors, which are used as 
primer binding sites for comparative PCR [15]. This method was described originally in the context of 
the  discovery  of  severe  acute  respiratory  syndrome  coronavirus  (SARS-CoV)  in  2004  [16]. 
Microarray-based diagnostic assays have also been used to characterize previously unknown viruses, 
such as SARS-CoVs [17], but require information on the genome of the virus or closely related viruses 
that are under investigation [18]. 
High  throughput  NGS  techniques  represent  a  powerful  tool  which  can  be  applied  to  
metagenomics-based strategies for the detection of unknown disease-associated viruses and for the 
discovery of novel human viruses [19,20]. Compared with microarray-based assays, NGS methods 
offer  the  advantage  of  higher  sensitivity  and  the  potential  to  detect  the  full  spectrum  of  viruses, 
including unknown and unexpected viruses.  
One of the first applications of NGS for pathogen discovery was the investigation of three patients 
who died of a febrile illness a few weeks after transplantation of solid organs from a single donor and 
for whom conventional microbiological and molecular tests, as well as microarray analysis for a wide 
range of infectious agents, had not been informative [21]. In this study, RNA was purified from blood, 
cerebrospinal fluid and tissue specimens from transplant recipients and, after digestion with DNase  
to  eliminate  human  DNA,  RNA  was  reverse-transcribed  and  amplified  with  random  primers. 
Amplification products were pooled and sequenced with the use of the 454 pyrosequencing platform. 
After subtraction of sequences of vertebrates and highly repetitive sequences, contiguous sequences 
were  assembled  and  compared  with  motifs  represented  in  databases  of  microbes,  leading  to  the 
identification  of  putative  protein  sequences  which  were  consistent  with  an  Old  World  arenavirus. Int. J. Mol. Sci. 2011, 12  7865 
 
 
Additional sequence analysis showed that it was a new arenavirus related to lymphocytic choriomeningitis 
viruses.  Further  serological  and  immunohistochemical  analyses  documented  that  the  virus  was 
transmitted through organ transplantation [21].  
A similar strategy, based on unbiased high-throughput sequencing using 454 pyrosequencing for the 
direct diagnosis of viral infections in clinical specimens, has been used in different diagnostic settings, 
such  as  the  investigation  of  patients  during  seasonal  influenza  and  norovirus  outbreaks  [22],  the 
identification of an astrovirus as a causative agent for encephalitis in a boy with agammaglobulinemia, 
after conventional methods had failed to identify an infectious agent [23], and the identification of a 
hemorrhagic fever-associated arenavirus from South Africa (Lujo virus) [24]. 
When implemented into virus-discovery methods based on shotgun sequencing, next-generation 
technologies  greatly  enhance  turnaround  time  and  sensitivity.  For  example,  the  454  system  was 
implemented into a virus discovery assay based on an improved version of the VIDISCA protocol to 
minimize rRNA contamination [25]. Likewise, the association of NGS techniques with rolling circle 
amplification (RCA), another method for virus discovery, could greatly increase its performance. RCA 
employs  the  PhiX29  polymerase  to  selectively  amplify  small  double  stranded  DNA  (dsDNA) 
molecules  and  is  used  to  amplify  circular  genomes  of  DNA  viruses  and  bacteria  plasmids  [26]. 
Recently, RCA led to the identification and whole genome sequencing of novel human papillomaviruses 
and polyomaviruses [27], including  human polyomaviruses 6  and 7  (HPyV6 and  HPyV7), detected  
in  cutaneous  swab  specimens  of  healthy  persons  [28],  and  trichodysplasia  spinulosa–associated 
polyomavirus (TSPyV), detected in skin lesions from immunocompromised patients [29]. 
Besides  454  pyrosequencing,  short-read-based  metagenomic  methods  using  the  Illumina  GA 
platform  have  also  been  used  to  detect  unknown  viruses  in  clinical  specimens.  The  Illumina  GA 
platform allowed to identify influenza A viruses from swab specimens and de novo assembly of its 
genome [30–32]. It also led to the detection of viral pathogens in nasopharyngeal aspirate samples 
from patients with acute lower respiratory tract infections [33], such as a new enterovirus, named 
enterovirus 109 (EV109) detected in a cohort of Nicaraguan children with viral respiratory illness [34].  
A comparative study of the analytical sensitivity of the two platforms, 454 pyrosequencing and 
Illumina GA, for the detection of viruses in biological samples was done on a set of samples which 
were artificially spiked with eleven different viruses [35]. The Illumina method had a much greater 
sensitivity than 454, approaching that of optimized quantitative real-time PCR. However, at low viral 
concentration in the specimen, the number of reads generated by the Illumina platform was too small 
for de novo assembly of viral genome sequences [35].  
Vector-borne viruses and zoonotic viruses represent another important and challenging field for 
viral discovery. The feasibility of detecting arthropod-borne viruses was explored in Aedes aegypti 
mosquitoes  experimentally  infected  with  dengue  virus  and  pooled  with noninfected  mosquitoes  to 
simulate samples derived from ongoing arbovirus surveillance programs [36]. Total RNA was purified 
from mosquito pools, reverse-transcribed using random primers and subjected to 454 pyrosequencing, 
which led to the correct identification of infected mosquito pools [36].  
Another  interesting  strategy  to  discover  arthropod-borne  viruses  exploits  the  property  of 
invertebrates to respond to infection by processing viral RNA genomes into siRNAs of discrete sizes. 
A recent study on small RNA libraries sequenced by NGS platforms [37] showed that viral small 
silencing RNAs produced by invertebrate animals are overlapping in sequence and can assemble into Int. J. Mol. Sci. 2011, 12  7866 
 
 
long contiguous fragments of the invading viral genome. Based on this finding, an approach of virus 
discovery in invertebrates by deep sequencing and assembly of total small RNAs was developed and 
applied to the analysis of contigs (i.e., a contiguous length of genomic sequences in which the order of 
bases  is  known  to  a  high  confidence  level)  assembled  from  published  small  RNA  libraries.  Five 
previously undescribed viruses from cultured Drosophila cells and adult mosquitoes were discovered, 
including three with a positive-strand RNA genome and two with a dsRNA genome [37]. This strategy 
for virus discovery based on deep sequencing of small RNAs has been also successfully used in plant 
virology [38]. 
Bats  are  reservoirs  for  emerging  zoonotic  viruses  that  cause  diseases  in  humans  and  livestock, 
including lyssaviruses, filoviruses, paramyxoviruses, and SARS-CoV. In a surveillance study focused 
on the discovery of bat-transmitted pathogens, gastrointestinal tissue obtained from bats was analyzed 
by coronavirus consensus PCR and unbiased high-throughput pyrosequencing that revealed the presence 
of sequences of a new coronavirus, related to those of SARS-CoV [39]. 
2.2. Detection of Tumor Viruses 
Computational  subtraction  analysis  of  data  obtained  using  conventional  shotgun  sequencing 
methods has been used to identify viral sequences (e.g., HBV, HCMV, human papillomaviruses 18 and 
16, HHV8, HCV, EBV and human spumavirus) in EST libraries derived from normal and cancerous 
tissues  [40]  and  in  post-transplant  lymphoproliferative  disorder  tissue  [41].  In  these  studies, 
computational subtraction analysis relied on sequence data gathered for other purposes as the yield of 
viral sequences was very low due to the predominance of human sequences. However, exploiting the 
great  amount  of  sequencing  data  achievable  by  NGS  methods,  computational  subtraction  analysis 
could become a method of choice for viral discovery. This approach has been used for the discovery of 
a new polyomavirus associated with most cases of Merkel cell carcinoma (MCC) [42]. MCC is a rare 
and aggressive human skin cancer that typically affects elderly and immunosuppressed individuals, a 
feature  which  was  suggestive  of  an  infectious  origin.  RNA  was  purified  from  MCC  samples  and 
analyzed by 454 pyrosequencing. Digital transcriptome subtraction of all human sequences led to the 
detection of a fusion transcript between a human receptor tyrosine phosphatase and a Large T antigen 
sequence  related  to  murine  polyomaviruses.  This  sequence  was  used  as  starting  point  for  whole 
genome sequencing and characterization of this previously unknown polyomavirus that was called 
Merkel cell polyomavirus (MCPyV). The presence of the virus in 80% MCC tissues but only in about 
10% of control tissues from various body sites, including the skin, and the demonstration that, in 
MCPyV-positive  MCCs,  viral  DNA  was  integrated  within  the  tumor  genome  in  a  clonal  pattern, 
strongly suggested the etiological role of the virus in the pathogenesis of MCC [42]. 
In a NGS study of the skin virome of a patient with MCC in comparison with healthy controls [43], 
another human polyomavirus strain was detected, which was nearly identical to the recently discovered 
HPyV9 polyomavirus [44] and closely related to the lymphotropic polyomavirus (LPV). Likewise, 
unbiased  high-throughput  sequencing  or  deep  sequencing  of  amplicons  generated  with  consensus 
primers targeting regions of the viral genome conserved within viral families, like the tumor-associated 
Polyomaviridae  and  Papillomaviridae,  allowed  the  discovery  and  characterization  of  many  new 
polyomavirus and papillomavirus genotypes in several animal species.  Int. J. Mol. Sci. 2011, 12  7867 
 
 
The  Papillomaviridae  family  includes  several  viral  species  and  at  least  189  completely 
characterized  papillomavirus  types  and  putative  new  types  are  continuously  found  [45].  High 
throughput 454 pyrosequencing of amplicons generated by consensus PCR of a conserved region of 
viral genome was used to detect and genotype HPV in cervical cytology specimens [46]. The method 
allowed the detection of HPV types which were present in low amount in multiple infections and  
had the potentiality to detect a broad spectrum of HPV types, subtypes, and variants [46]. A similar 
approach was used to detect and genotype cutaneous HPV types in a large series of squamous cell 
carcinoma of the skin and other skin lesions [47]. Several different HPV types were detected, including 
novel putative cutaneous HPVs [47]. 
Investigation of retrovirus and retroviral vector integration sites in host cell chromosomes is another 
field of viral oncology which received a great contribution from NGS technologies. The use of viral 
vectors that integrate in host genome for gene transfer may cause malignant transformation due to 
activation of host proto-oncogenes or inactivation of tumor-suppressor genes, as a consequence of viral 
vector integration within these genes [48–50]. Deep sequencing technology has been used to map the 
integration sites of retroviruses and HIV [51], as well as retroviral and HIV-based vectors for gene 
therapy  and  cell  reprogramming  [52–54].  Deep  sequencing  methods  for  detection  of  retrovirus 
integration are based on 454 pyrosequencing of products of ligation-mediated PCR (LM-PCR) [55,56] 
or linear amplification–mediated PCR (LAM-PCR) [57]. Both LM-PCR and LAM-PCR use restriction 
enzymes to fragment the DNA of interest containing proviruses. Then, digested DNA is ligated with a 
compatible  linker  and  amplified  by  PCR  using  primers  that  anneal  in  the  LTR  and  in  the  linker 
sequence. Nested primers containing linkers for the 454 protocol are then used for a second PCR, 
which  is  processed  by  454  high-throughput  sequencing.  A  LAM-PCR  method  without  the  use  of 
restriction enzymes was also developed for high throughput sequencing [58]. Recently, a new method 
was developed for recovering sites of integrated DNA based on the bacterial transposase MuA. The 
transposase is used to introduce adaptors into genomic DNA to allow PCR amplification and analysis 
by 454 pyrosequencing. This method could avoid the bias associated with restriction enzymes and 
recovered integration sites in a near random fashion. It provided a measure of cell clonal abundance, 
which  is  crucial  for  detecting  expansion  of  cell  clones  that  may  be  a  prelude  to  malignant 
transformation [59].  
2.3. Characterization of the Human Virome 
The human microbiome is the entire population of microbes (i.e., bacteria, fungi, and viruses) that 
colonize the human body. Metagenomics refers to culture-independent studies of the collective set of 
genomes of mixed microbial communities and applies to explorations of all microbial genomes in 
consortia  that  reside  in  environmental  niches,  in  plants,  or  in  animal  hosts,  including  the  human  
body  [60–62].  The  “metagenome”  of  microbial  communities  that  occupy  human  body  niches  is 
estimated to have a gene content approximately 100-fold greater than the human genome [63]. These 
diverse  and  complex  collections  of  genes  encode  a  wide  array  of  biochemical  and  physiological 
functions that may be relevant in healthy and disease conditions. 
Metagenomics strategies are generally based on whole genome shotgun sequencing of nucleic acids 
purified from a specimen. In case of bacteria metagenomics, analysis can be simplified by exploiting Int. J. Mol. Sci. 2011, 12  7868 
 
 
universal and conserved targets, such as 16S rRNA genes, which have both conserved regions that can 
be  targeted  by  PCR  primers,  and  intervening  variable  sequences  that  facilitate  genus  and  species 
identification [60,61]. At variance, no conserved ubiquitous viral sequences are available for broad 
amplification of viral genomes and methods to enrich samples with viral particles can only be used. In 
addition,  viral  metagenomics  analyses,  which  have  been  applied  so  far  mostly  in  environmental 
samples like fresh water, reused wastewater, and ocean water [64–67], have shown that many of the 
detected viral sequences are unique and represent unknown viral species. Thus, viral sequences may be 
missed even by shotgun sequencing [68].  
A recent study [69] developed a bioinformatic annotation strategy for identification and quantitative 
description of human pathogenic viruses in virome data sets and  applied this strategy to  annotate 
sequences of viral DNA and RNA (cDNA) extracted from sewage sludge residuals resulting from 
municipal  wastewater  treatment  (biosolids),  which  were  obtained  by  454  pyrosequencing.  In  this 
experimental model, within the 51,925 annotated sequences, 94 DNA and 19 RNA sequences were 
identified  as  human  viruses.  Virus  diversity  included  environmentally  transmitted  agents  such  as 
parechovirus,  coronavirus,  adenovirus  and  aichi  virus,  as  well  as  viruses  associated  with  chronic 
human infections, such as human herpesviruses and hepatitis C virus [69]. 
In  the  diagnostic  setting,  metagenomic  approaches  could  be  used  for  systematic  analysis  of  
samples collected from patients with unexplained illness, especially in the context of outbreaks and 
epidemics [70,71]. As mentioned in the above section, application of high throughput NGS methods in 
viral metagenomics can greatly enhance the chances to identify viruses in clinical samples, including 
viruses that are too divergent from known viruses to be detected by PCR or microarray techniques 
(reviewed in ref. [20]). An attractive application of metagenomic approaches is the study of influenza, 
given the constant threat of antigenic drift and shift. Deep sequencing strategies can be used to monitor 
the emergence of mutations that confer virulence or resistance to antiviral drugs, to detect influenza 
viruses in clinical samples, and to identify viral quasispecies [22,31,32]. In addition, deep sequencing 
of clinical samples allows to identify and characterize not only novel pathogens but also the microbiota 
and host response to infection [32].  
The  study  of  the  human  virome  includes  also  the  description  of  viral  communities—including 
bacteriophages—in  human  body  and  their  relationship  with  health  and  disease.  Examples  are  the 
characterization of fecal viromes (mainly phages) and their relations with bacterial metagenome [72] 
and the characterization of the virome in the skin of healthy individuals [28]. 
2.4. Full-Length Viral Genome Sequencing 
Like viral metagenomics, sequencing of full-length viral  genomes is a difficult task due to the 
presence of contaminating nucleic acids of the host cell and other agents in viral isolates. In fact, 
preparation of a simple shotgun sequencing DNA library, the most comprehensive approach, or of a 
library  of  cDNA  synthesized  from  RNA  with  random  priming,  results  in  a  huge  amount  of  host 
specific instead of a comprehensive representation of the viral sequences, even in the presence of a 
very high viral load [21,31,73]. Very high throughput sequencing techniques, such as SOLiD platform, 
could be used to obtain sufficient sequence coverage [74], but the length of reads might be too short to 
allow de novo assembly of viral genomes and methods that provide longer reads, like 454 and Illumina Int. J. Mol. Sci. 2011, 12  7869 
 
 
technology, might be preferable [31,32]. Several techniques have been used to enrich virions or viral 
nucleic acids from cell culture or from host tissue and fluids before extracting the genomic DNA/RNA, 
in order to limit the contamination from host nucleic acids. One of these methods is ultracentrifugation, 
but this procedure may be very time-consuming and laborious with uncertain outcome [75]. Other 
methods are based on enrichment of viral nucleic acids by using capture probes or PCR amplification 
targeting conserved genome segments [76,77] or, vice versa, by depletion of host nucleic acids by 
probing  total  RNA  with  labeled  host  nucleic  acid  [78].  Other  approaches  could  be  enrichment  of 
dsRNA virus genomes [79] or circular dsDNA viral genomes by RCA [28,29]. 
2.5. Investigation of Viral Genome Variability and Characterization of Viral Quasispecies  
High mutation rates inherent to replication of RNA viruses create a wide variety of mutants that are 
present in virus populations, which are often referred to as quasispecies [80]. The diffuse, “cloud-like” 
nature  of  viral  populations  allows  them  to  rapidly  adapt  to  changing  replicative  environments  by 
selecting preexisting variants with better fitness [81,82]. Thus, many important virus properties cannot 
be explained by a mere consensus sequence, but require knowledge about the microvariants present in viral 
populations. These sequence variants may be critically relevant to viral evolution and spread, virulence, 
evasion of the immune response, anti-viral drug resistance, and vaccine development and manufacture.  
The use of deep sequencing data for mutation analysis in viral genomes has required the development 
of computational methods for estimation of the quality of sequences and for error correction, algorithms 
for sequence alignment and haplotype reconstruction, statistical models to infer the frequencies of the 
haplotypes in the population, for comparative analysis and for their visualization [83–86]. 
Among  RNA  viruses,  HIV  quasispecies  have  been  extensively  investigated  because  of  their 
relevance for vaccine design and response to antiviral drug therapy [87]. Within infected individuals, 
HIV is highly heterogeneous owing to rapid turnover rates, high viral load, and a replication mediated 
by the error-prone reverse transcriptase enzyme that lacks proofreading activity. High variability is 
also the consequence of recombination, which can shuttle mutations between viral genomes and lead to 
major antigenic shifts or alterations in virulence [88]. An example of application of NGS for analysis 
of HIV quasispecies is the use of massive parallel 454 pyrosequencing with the shotgun approach to 
characterize the full length genome of an HIV-1 BF recombinant and its quasispecies heterogeneity in 
a patient who died from multiorgan failure during seroconversion [89]. Another fascinating application 
of deep sequencing in HIV research is the use of the 454 pyrosequencing methods to analyze the 
variable  regions  of  heavy  and  light  chains  of  neutralizing  antibodies  against  HIV  in  the  blood  
obtained from HIV-1-infected individuals, in order to understand how broadly neutralizing antibodies 
develop [90]. But the most relevant application of NGS in HIV diagnostics is the detection of anti-viral 
drug resistant minor variants, which will be discussed in the next section.  
Analysis of full-length viral genome and quasispecies was also applied to other RNA viruses. Deep 
sequencing with the Illumina platform on total RNAs extracted from the lung of a patient who died  
of  viral  pneumonia  due  to  pandemic  2009  influenza  A  virus  (A/H1N1/2009)  revealed  nucleotide 
heterogeneity  on  hemagglutinin  as  quasispecies,  leading  to  amino  acid  changes  on  antigenic  sites 
which could be relevant for antigenic drift [31]. Int. J. Mol. Sci. 2011, 12  7870 
 
 
Mutations of human rhinovirus (HRV) genome were explored in a lung transplant recipient infected 
with the same HRV strain for more than two years [91]. Analysis of complete HRV genome sequences 
by both classical and Illumina ultra-deep sequencing of samples collected at different time points in the 
upper and lower respiratory tracts showed that HRV populations in the upper and lower respiratory 
tract were phylogenetically indistinguishable over the course of infection, likely because of constant 
viral population mixing. Nevertheless, signatures of putative adaptation to lower airway conditions 
appeared after several months of infection, with the occurrence of specific changes in the 5’UTR 
polypyrimidine  tract  and  the  VP2  immunogenic  site  2  of  HRV  genome,  which  might  have  been 
relevant for viral growth at lower airway conditions [91].  
Populations of DNA viruses are considered less complex and variable when compared to RNA 
viruses. However, data from deep sequencing of DNA virus genomes have revealed that complex 
mixtures of viral genotypes may be present in infected subjects and that positive selection could have 
contributed to the divergence of different strains. This is the case of human cytomegalovirus (HCMV), 
which  establishes  lifelong  latent  infections  in  humans  and  may  reactivate  and  cause  severe  
life-threatening disease in immunocompromised patients. High intra-host variability of HCMV genome 
was demonstrated in lung transplant recipients by deep sequencing of the amplicons of three variable 
HCMV genes [92] and in neonates with congenital HCMV infection by deep sequencing of long range, 
overlapping  amplicons  covering  the  entire  HCMV  genome  [93].  Since  PCR  amplification  and 
sequencing  can  introduce  errors  in  their  own,  which  could  be  misinterpreted  as  mutation  or 
polymorphisms,  deep  sequencing  studies  have  to  develop  protocols  and  algorithms  to  estimate 
experimental error and to filter false positive results. In the studies reported here on HCMV genome 
variability, experimental error rate was estimated by using arbitrary criteria [92] or an algorithm based 
on experimental data obtained from deep sequencing analysis of a control HCMV genome cloned in a 
BAC vector [93].  
Deep sequencing showed also variability of herpes simplex virus 1 (HSV-1) genome and allowed to 
demonstrate virulence genes. Using Illumina high-throughput sequencing, genome sequences of both a 
laboratory strain (F) and a low-passage clinical isolate (H129) were obtained and compared with the 
available genome sequence of a more virulent isolate of HSV-1 (strain 17) [94]. The HSV-1 H129 
strain, isolated from the brain of an encephalitic patient, is the only virus known to transit neural 
circuits exclusively in an anterograde direction [95]. Whole genome sequencing demonstrated many 
protein-coding variations between strains F and H129 and the genome reference strain 17 and some 
genes were proposed to be responsible of the anterograde mutant phenotype of strain H129, including 
the neurovirulence protein ICP34.5, while a frameshift mutation in the UL13 kinase could account for 
decreased neurovirulence of strain F [94]. 
2.6. Monitoring Antiviral Drug Resistance 
Deep sequencing by NGS techniques is being increasingly used in the clinical practice to detect low 
abundance drug resistant HIV variants and, with the recent availability of new drugs active against 
hepatitis C virus (HCV), also for the detection of HCV minor variants.  
Conventional direct sequencing of RT-PCR products (referred to as “population sequencing”) is the 
gold standard in HIV resistance testing and is used to detect drug-resistance mutations in the molecular Int. J. Mol. Sci. 2011, 12  7871 
 
 
targets of HIV-1 therapy, i.e., reverse transcriptase, protease, integrase, and V3 loop of the HIV env 
gene. A major limitation of direct PCR sequencing, however, is its inability to detect drug-resistant 
variants present in less than 20–25% of the heterogeneous virus population existing in a patient’s 
plasma sample [96]. Several studies have shown that minor drug-resistant variants that are not detected 
by  population-based  sequencing  are  clinically  relevant  in  that  they  are  often  responsible  for  the 
virological failure of a new antiretroviral treatment regimen [97–99].  
Clonal  sequencing  of  RT-PCR  products  by  454  pyrosequencing  offers  the  advantage  of  high 
sensitivity for minor variants and a relatively long sequence length that facilitates the characterization 
of the linkage amongst resistance mutations and avoids the risk to miss mutations due to sequence 
variation  around  the  site  under  investigation.  The  application  of  454  sequencing-based  resistance 
testing in clinical setting, however, requires careful consideration of potential technical errors that can 
be  introduced  in  the  experimental  protocol  and  in  data  analysis  in  order  to  discriminate  between 
experimentally introduced errors and true variants [87,100,101]. Data analysis issues are discussed in 
Section 2.9. 
Several studies that employed 454 pyrosequencing for deep analysis of mutations in HIV protease 
and  reverse  transcriptase  genes  demonstrated  the  accuracy  of  this  technique  in  detecting  all  
drug-resistance mutations identified by population sequencing, and the ability to detect low-frequency 
mutations  undetectable  by  population  sequencing  [100,102,103].  In  addition,  several  studies 
demonstrated that drug-resistance mutations detected by 454 had a significant impact on virological 
failure  [103–107]  while  others  did  not  find  a  strong  association  of  low-frequency  mutations  with 
clinical  responses  [108,109].  Deep  sequencing  using  the  454  platform  has  been  also  applied  to 
investigate  drug-resistance  mutations  against  the  more  recently  approved  integrase  inhibitors  and 
CCR5 antagonists.  
Drug-resistance mutations to integrase inhibitors occur in the integrase gene. These mutations were 
detected by deep sequencing at very low levels if at all prior to initiating therapy [110] and could be 
selected by previous drug pressure [111]. Resistance to CCR5 antagonists, like maraviroc, occur by 
outgrowth of CXCR4-tropic HIV variants, i.e., viruses that use the CXCR4 coreceptor [112] or via 
mutations in the viral envelope protein [113–116]. Coreceptor usage can be screened using phenotypic 
coreceptor  tropism  assays,  based  on  recombinant  virus  technology,  or  genotypic  tests,  based  on 
sequencing  of  the  V3  loop  of  HIV  env  gene  [117].  Phenotypic  assays  have  good  sensitivity  and 
specificity, but they are time consuming, expensive, and require special laboratory facilities; thus they 
are not convenient as diagnostic tests in clinical practice. Genotyping methods based on population 
sequencing represent a more feasible alternative, but their sensitivity for the detection of minority 
variants  is  lower  than  phenotypic  assay  (about  10–20%)  and  this  represents  a  problem,  since  the 
proportion  of  CXCR4-tropic  HIV  variants  before  initiation  of  therapy  is  generally  very  low.  In 
addition, the algorithms used for interpretation of sequencing results may underestimate the impact of 
some  mutations  in  viral  tropism  [118].  Deep  sequencing  by  using  454  has  been  used  in  several  
studies [119–123], including large clinical trials, to determine viral tropism and has been demonstrated 
to  be  comparable  in  sensitivity  and  specificity  with  phenotypic  assays  in  detecting  CXCR4-using 
variants.  According  to  data  reported  to  date,  the  clinical  threshold  for  detection  of  CXCR4-tropic 
variants  might  range  between  2–10%  [118].  With  this  threshold,  454  pyrosequencing  at  ≥1% 
sensitivity for minority variants can represent a valuable diagnostic tool for viral tropism testing. In Int. J. Mol. Sci. 2011, 12  7872 
 
 
addition,  deep  sequencing  of  relatively  long  reads  allows  defining  the  contribution  of  multiple 
mutations in a single viral genome. This information could improve the performance of interpretation 
algorithms as compared with population sequencing.  
Deep sequencing based on the 454 technology has been also applied for the detection of nucleoside 
and nucleotide reverse-transcriptase inhibitor resistance in HBV. The NGS method was more sensitive 
for the detection of rare HBV drug resistance mutations than conventional methods based on population 
sequencing or reverse hybridization [124,125]. In addition, deep sequencing allowed to identify G-to-A 
hypermutation mediated by the apolipoprotein B mRNA editing enzyme, which was estimated to be 
present in 0.6% of reverse-transcriptase genes [124]. 
Finally, with the availability of new drugs targeting HCV protease and polymerase, the experience 
of drug-resistance mutation and quasispecies analysis achieved with HIV is being translated to HCV. 
Also for HCV, deep sequencing technologies seem a promising tool for the study of minority variants 
present in the HCV quasispecies population at baseline and during antiviral drug pressure, giving new 
insights into the dynamics of resistance acquisition by HCV [126,127]. 
2.7. Epidemiology of Viral Infections and Viral Evolution  
High throughput sequencing is being used to investigate the epidemiology of viral infections and 
viral evolution, addressing issues such as viral superinfection (e.g., HIV superinfection, which occurs 
when a previously infected individual acquires a new distinct HIV strain) [128], tracing the evolution 
and spread of viral strains, such as the emergence, evolution and worldwide spread of HIV [88], tracing 
the transmission of viruses among individuals [129], or modeling the evolution of viruses within the 
host and the mechanism of immune escape, balanced with replication fitness, such as in the case of 
HIV and HCV infection [127,130,131]. 
2.8. Quality Control of Live-Attenuated Viral Vaccines 
Intrinsic genetic instability of RNA viruses may lead to the accumulation of virulent revertants 
during manufacture of live viral vaccines, requiring rigorous quality control to ensure vaccine safety. 
High  throughput  deep  sequencing  methods  have  been  proposed  as  tools  for  monitoring  genetic 
consistency of live viral vaccines. Deep sequencing was used to analyze lots of oral poliovirus vaccine 
and the detected neurovirulence mutations were identical to the mutation detected with the standard 
method based on PCR and restriction enzyme cleavage [132]. Patterns of mutations present at a low 
level in vaccine preparations were characteristic of seed viruses used for their manufacture and could 
be used for identification of individual batches [132]. Deep sequencing was also used to examine eight 
live-attenuated viral vaccines, i.e., trivalent oral poliovirus, rubella, measles, yellow fever, varicella-zoster, 
multivalent  measles/mumps/rubella,  and  two  rotavirus  live  vaccines  [133].  The  method  allowed 
identification  of,  not  only  mutations  and  minority  variants  relative  to  vaccine  strains,  but  also 
sequences  of  adventitious  viruses  from  the  producer  avian  and  primate  cells.  The  results  were  in 
agreement with those obtained by using a panmicrobial microarray [133].  Int. J. Mol. Sci. 2011, 12  7873 
 
 
2.9. Data Analysis Issues 
An aspect that should not be neglected when dealing with NGS data, is the bioinformatics analysis 
and issues concerning sequencing output. There are inherent strengths and weaknesses in the different 
platforms  as  reported  in  Table  1.  For  example,  454  technology  is  well  suited  for  small  de  novo 
sequencing  projects  and  amplicon  studies,  given  its  read  length  output  that  presently  reaches  the 
average length of sequences produced with Sanger method. The main issue to be aware of concerns the 
homopolymer length, due to signal thresholding of the incorporated nucleotides. SOLiD platform is 
not presently suitable for amplicon studies due to the short read length, but exhibits an extremely high 
throughput capacity. Illumina has a superior read length and is not affected by homopolymers but, as 
SOLiD, shows low coverage of AT rich regions [134]. Other platforms present in Table 1 (with the 
exclusion of the GS Junior, which shares the same features of 454 FLX but has a lower throughput) are 
still in development and not yet evaluated in their diagnostic potential.  
Besides the specific limits of the different platforms, other common issues should be taken into 
account and carefully considered. The first sources of problems are certainly chimerical sequences, 
point mutations and insertions/deletions which occur during reverse transcription, PCR amplification 
or sequencing itself. In addition, PCR amplification bias might impact the relative frequencies of viral 
variants. The process of “data cleaning” consists of three main steps: sequence filtering, alignment and 
error correction, for which a panel of methods has been proposed [84,135,136]. Briefly, the filtering 
phase removes the low-quality sequences from the dataset, while the error correction separates true 
variants from those due to experimental noise. This step is based on the idea that errors are randomly 
distributed  with  low  frequency,  while  sequences  with  real  mutations  can  be  clustered  and  their 
abundance quantified. A cluster of reads presenting the same mutations represents a haplotype and the 
size of the cluster is the haplotype frequency. Global haplotypes are more difficult to be identified, 
since the reads must be assembled in larger contigs and a unique solution in aligning overlapping reads 
is not guaranteed. To this respect, the advantage of 454 platform for haplotype reconstruction studies is 
evident, thanks to its longer reads output. 
As concerns the data analysis step, a multitude of software has been developed for very different 
applications of NGS. Nevertheless, if on the one hand this availability of methods greatly eases the 
task, on the other hand available algorithms for both genome assembly and amplicon analysis present 
limitations  or  drawbacks  [137]  which  require  custom  made  scripting  and  in-house  resolution  of 
bioinformatics problems caused by specific needs [46]. The direct consequence is that data analysis 
can be no more sustained by the wet-lab researcher alone, but requires the acquisition of computer 
skills and bioinformatics expertise.  
3. Conclusions 
Next-generation high throughput sequencing technologies have become available in the last few 
years and are in continuous development and improvement. They have been widely used in many 
projects, e.g., whole genome sequencing, metagenomics, small RNA discovery and RNA sequencing. 
Their common feature is the extremely high throughput data generation. As a result, new issues have 
to be addressed in order to exploit the full potential of these new instruments: firstly, the data analysis Int. J. Mol. Sci. 2011, 12  7874 
 
 
step has become very time consuming and requires a competent amount of manpower and expertise in 
bioinformatics; secondly, adequate computing resources are necessary to handle the data produced. 
Diagnostic virology is one of the most successful applications for NGS and exciting results have 
been achieved in the discovery and characterization of new viruses, detection of unexpected  viral 
pathogens in clinical specimen, ultrasensitive monitoring of antiviral drug resistance, investigation of 
viral diversity, evolution and spread, and evaluation of the human virome. With the decrease of costs 
and improvement of turnaround time, these techniques will probably become essential diagnostic tools 
in clinical routines. 
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